Delving into the Latest Updates on Novatim Immune Therapeutics (Zhejiang) Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

Antibody drug conjugate (ADC)

Autologous CAR-T

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	10
Hemic and Lymphatic Diseases	4
Immune System Diseases	2
Nervous System Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Autologous CAR-T	3
Antibody drug conjugate (ADC)	3
Biological products	1
Bispecific antibody	1
Fusion protein	1

Top 5 Target	Count

IL-2R x PD-1	1
TM4SF1(transmembrane 4 L six family member 1)	1
EGFR x c-Met	1
c-Met(Hepatocyte growth factor receptor)	1
BCMA x CD19	1

This trial is a first-in-human, multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of KY-0301 as monotherapy in patients with advanced solid tumors. This trial will be conducted at approximately multi-sites nationwide, and approximately110
212 participants with unresectable locally advanced or metastatic solid tumors will be invited to participate. The study consists of three parts: Phase I dose escalation & dose expansion phases of KY-0301 as monotherapy, Phase II cohort expansion phase of KY-0301 as monotherapy.

Start Date01 May 2025

Sponsor / Collaborator

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

CTR20242409

/ RecruitingPhase 1

评价 KQ-2003 CAR-T 细胞注射液在 POEMS 综合征患者中的安全性、耐受性、初步有效性和药代动力学特征的I 期临床试验

[Translation] A Phase I clinical trial to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetic characteristics of KQ-2003 CAR-T cell injection in patients with POEMS syndrome

主要目的：（1）评价 KQ-2003 CAR-T 细胞在 POEMS 综合征患者的剂量限制性毒性（DLT），确定其最大耐受剂量（MTD）或最佳剂量。次要目的：（1）评价 KQ-2003 CAR-T 细胞在 POEMS 综合征患者的初步有效性；（2）评估 KQ-2003 CAR-T 细胞在 POEMS 综合征患者体内的药代动力学（PK）；（3）评估 KQ-2003 CAR-T 细胞在 POEMS 综合征患者体内的药效动力学（PD）特征；（4）评估 KQ-2003 CAR-T 细胞在 POEMS 综合征患者体内的免疫原性。

[Translation]

Primary objectives: (1) To evaluate the dose-limiting toxicity (DLT) of KQ-2003 CAR-T cells in patients with POEMS syndrome and determine its maximum tolerated dose (MTD) or optimal dose. Secondary objectives: (1) To evaluate the preliminary efficacy of KQ-2003 CAR-T cells in patients with POEMS syndrome; (2) To evaluate the pharmacokinetics (PK) of KQ-2003 CAR-T cells in patients with POEMS syndrome; (3) To evaluate the pharmacodynamic (PD) characteristics of KQ-2003 CAR-T cells in patients with POEMS syndrome; (4) To evaluate the immunogenicity of KQ-2003 CAR-T cells in patients with POEMS syndrome.

Start Date11 Oct 2024

Sponsor / Collaborator

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

NCT06518876

/ Not yet recruitingPhase 1

A Phase 1 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characterization of KQ-2003 for Patients With Relapsed/Refractory POEMS Syndrome

This is a multicenter, open-label, dose-escalation/expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and determine the recommended dose of KQ-2003 CAR T-cells for patients with Relapsed/Refractory POEMS Syndrome

Start Date31 Aug 2024

Sponsor / Collaborator

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

100 Clinical Results associated with Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Login to view more data

100 Deals associated with Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

3

Preclinical

IND Application

1

2

Phase 1

Phase 2

2

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

KY-0301 ( EGFR x c-Met )	Advanced Malignant Solid Neoplasm More	Phase 1/2
KQ-2003 ( BCMA x CD19 )	Refractory Multiple Myeloma More	Phase 1/2
KY-0118 ( IL-2R x PD-1 )	Locally Advanced Malignant Solid Neoplasm More	Phase 1
KQ-2002 ( CD19 x CD22 )	B-cell lymphoma recurrent More	Phase 1
KQ-L6 ( TM4SF1 )	Solid tumor More	IND Application